Tisotumab vedotin
Tivdak · Antibody-drug conjugate (tissue factor/MMAE)
Ocular/bleeding toxicity dominates; renal involvement essentially unreported.
Antibody-drug conjugate (FRα/DM4)
Elahere · MIRV
Antibody-drug conjugate (FRα/DM4) · approved 2022 · 4 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An FRα/DM4 conjugate for ovarian cancer — ocular and GI toxicity dominate; renal data are emerging.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is not a prominent trial signal; ocular (keratopathy/blurred vision, ~50% any-grade across pooled trials) and GI/fatigue toxicities dominate. AKI is case-level and chiefly volume-mediated (GI toxicity). Renal-specific incidence is not quantified.Source: Moore et al., N Engl J Med 2023 (MIRASOL)
Prerenal injury is variable and tracks with GI toxicity during treatment cycles.
Distilled from: “Variable; tracks with GI toxicity during treatment cycles.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Antibody-drug conjugate targeting folate receptor alpha (FRα) and delivering the maytansinoid microtubule inhibitor DM4 via a cleavable disulfide linker. Approved for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Class-level context for the major non-renal toxicities of the Antibody-drug conjugate (FRα/DM4) class.
Hematologic
Cytopenias, thrombosis, TMA
Ophthalmic
Keratopathy, uveitis, retinopathy
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Jul 2025) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: OCULAR TOXICITY ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated [see Dosage and Administration ( 2.3 )] . Administer prophylactic artificial tears and ophthalmic topical steroids [see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.1 )] . Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose [see Dosage and Administration ( 2.4 ) and Warnings and Precautions ( 5.1 )] . Discontinue ELAHERE for Grade 4 ocular toxicities [see Dosage and Administration ( 2.4 ) and Warnings and Precautions ( 5.1 )] . WARNING: OCULAR TOXICITY See full prescribing information for complete boxed warning. ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. ( 5.1 , 6.1 ) Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated. ( 2.3 ) Administer prophylactic artificial tears and ophthalmic topical steroids. ( 2.3 , 5.1 )…
Renal impairment — from the label
No dosage adjustment of ELAHERE is recommended for patients with mild to moderate renal impairment (CLcr 30 to 89 mL/min). The effect of severe renal impairment (CLcr 15 to < 30 mL/min) or end-stage renal disease on ELAHERE is unknown [see Clinical Pharmacology ( 12.3 )] .
Kidney rows of the label's dosage tables
From the ELAHERE label (Jul 2025) · DailyMed
No row of this label's 3 dosage tables names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 1,814 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
236 of 1,814 reports
Reported with hospitalization
300 of 1,814 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Mirvetuximab soravtansine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Tivdak · Antibody-drug conjugate (tissue factor/MMAE)
Ocular/bleeding toxicity dominates; renal involvement essentially unreported.
Elspar · Enzyme
Rare AKI; pancreatitis-mediated.
Welireg · HIF-2α inhibitor
Anemia/hypoxia; emerging renal profile in VHL/RCC.
DTIC · Alkylator
Rare hepatic veno-occlusive disease; minimal direct renal injury.
Halaven · Microtubule inhibitor
Reduced clearance in renal impairment.
Camptosar · Topoisomerase I inhibitor
Diarrhea-driven prerenal AKI.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.